Immunology

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. Presentations by principal investigator William Wijns, M.D., Ph.D. of the Cardiovascular Center in Aalst, Belgium, highlighted results of long-term clinical follow-up of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System. MiStent SES^® is a thin-strut drug-eluting stent with a bioabsorbable polymer intended to optimize vessel healing in patients with coronary artery disease.

"The two- and three-year data demonstrate the long-term safety and efficacy of MiStent SES's unique design," commented Dr. Wijns. "Importantly, the crystal sirolimus component of this novel stent provides a slow, controlled release that maintains therapeutic levels of drug in tissue for up to nine months, achieving long-term drug delivery without long-term polymer exposure."